Indications
Treatment of coronavirus disease 2019 (COVID-19).
Composition
- Active substance
- molnupiravir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lagevrio
- Active substance
- molnupiravir
- ATC code
- J05A
- Therapeutic area
- COVID-19 virus infection
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/005789